Skip to main content
ID

Ipsum Diagnostics

Ipsum Diagnostics is a molecular diagnostics laboratory utilizing polymerase chain reaction (PCR) technology to detect infectious disease pathogens and antibiotic resistance genes. The company provides rapid test results that enable timely and effective treatment, improving patient outcomes in various medical conditions.

Atlanta, United StatesFounded 202022500+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Infectious disease diagnosis often faces delays due to slow turnaround times in traditional laboratory testing, hindering timely treatment and potentially worsening patient outcomes. The need for rapid and accurate detection of pathogens and antibiotic resistance genes is critical for effective clinical decision-making.

Solution

Ipsum Diagnostics offers molecular diagnostic services utilizing polymerase chain reaction (PCR) technology for the rapid detection of infectious disease pathogens and antibiotic resistance genes. Their PCR panels provide quick and precise results, enabling clinicians to make informed treatment decisions and improve patient care. By offering faster turnaround times compared to conventional methods, Ipsum Diagnostics facilitates timely interventions and reduces the risk of complications associated with delayed diagnoses. The company's comprehensive testing menu includes panels for bacterial/wound infections, onychomycosis, fungal infections, respiratory pathogens, and urinary/genital tract infections.

Target Audience

Ipsum Diagnostics primarily serves healthcare providers, including physicians, hospitals, and clinics, who require rapid and accurate diagnostic information for the management of infectious diseases.

Features

  • Polymerase chain reaction (PCR) technology for rapid and accurate pathogen detection
  • Comprehensive panels for bacterial/wound infections, onychomycosis (pathology stains and PCR), fungal infections, respiratory pathogens, and urinary/genital tract infections
  • Upcoming panels for blood and toxicology testing, as well as Next-Gen Sequencing (NGS) panels
  • Quicker turnaround times compared to traditional laboratory methods
This profile is AI-generated and may contain inaccuracies.